comparemela.com

Latest Breaking News On - Sarepta therapeutics daily - Page 1 : comparemela.com

Bellevue Group AG Sells 4,466 Shares of Sarepta Therapeutics, Inc (NASDAQ:SRPT)

Bellevue Group AG trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.8% during the fourth quarter, Holdings Channel reports. The fund owned 237,286 shares of the biotechnology company’s stock after selling 4,466 shares during the quarter. Bellevue Group AG’s holdings in Sarepta Therapeutics were worth $22,881,000 as of its most recent […]

Bellevue Group AG Lowers Position in Sarepta Therapeutics, Inc (NASDAQ:SRPT)

Bellevue Group AG trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,286 shares of the biotechnology company’s stock after selling 4,466 shares during the […]

Eagle Asset Management Inc Has $20 85 Million Holdings in Sarepta Therapeutics, Inc (NASDAQ:SRPT)

Eagle Asset Management Inc. lessened its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 0.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 216,168 shares of the biotechnology company’s stock after selling 2,054 shares during the quarter. Eagle Asset Management […]

Sarepta Therapeutics (NASDAQ:SRPT) Rating Reiterated by Royal Bank of Canada

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sector perform” rating reissued by equities researchers at Royal Bank of Canada in a note issued to investors on Tuesday, MarketBeat reports. They currently have a $142.00 price target on the biotechnology company’s stock, down from their prior price target of $157.00. Royal Bank of […]

Sarepta Therapeutics, Inc (NASDAQ:SRPT) Given Consensus Rating of Moderate Buy by Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.